Non-nicotine pharmacotherapies for smoking cessation

Respiratory Medicine

Volumn 99, Issue 10, 2005, Pages 1203-1212

  McRobbie, H ^a,b   Lee, M ^a   Juniper, Z ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bupropion; Clonidine; Non nicotine; Nortriptyline; Smoking cessation

Indexed keywords

ACETATE SILVER; AMFEBUTAMONE; ANXIOLYTIC AGENT; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; BUSPIRONE; CLONIDINE; FLUOXETINE; LAZABEMIDE; LOBELINE; MECAMYLAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NICOTINE; NORTRIPTYLINE; ONDANSETRON; OPIATE ANTAGONIST; PAROXETINE; PLACEBO; RIMONABANT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILVER DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ARGYRIA; ARTICLE; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; HYPERTENSIVE CRISIS; HYPOGLYCEMIA; INSOMNIA; LIVER TOXICITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; TREATMENT INDICATION; URINE RETENTION; VISUAL IMPAIRMENT; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BUPROPION; CLONIDINE; DOPAMINE UPTAKE INHIBITORS; HUMANS; NORTRIPTYLINE; RANDOMIZED CONTROLLED TRIALS; SMOKING; SMOKING CESSATION;

EID: 24344468688     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.05.016     Document Type: Article

References (55)

1. M. Ezzati A.D. Lopez Regional, disease specific patterns of smoking-attributable mortality in 2000 Tob Control 13 2004 388-395
2. 1. The Lung Health Study J Am Med Assoc 272 1994 497-1505
3. S. Hurd R. Pauwels Global initiative for chronic obstructive lung diseases (GOLD) Pulm Pharmacol Ther 15 2002 353-355
4. Royal College of Physicians Nicotine addiction in Britain. A report of the tobacco advisory group of the Royal College of Physicians 2000 RCP London
5. K.O. Haustein Tobacco or health: Physiological and social damages caused by tobacco smoking 2003 Springer Berlin
6. J.R. Hughes S.W. Gust K. Skoog R.M. Keenan J.W. Fenwick Symptoms of tobacco withdrawal. A replication and extension Arch Gen Psychiatry 48 1991 52-59
7. C. Silagy T. Lancaster L. Stead D. Mant G. Fowler Nicotine replacement therapy for smoking cessation In: The Cochrane Library, Issue 3 2004 Wiley Chichester, UK
8. G. Sutherland Evidence for counseling effectiveness for smoking cessation J Clin Psychiatr Monogr 18 2003 22-34
9. J.R. Hughes Non-nicotine pharmcotherapies for smoking cessation J Drug Dev 6 1994 197-203
10. J.R. Hughes L.F. Stead T. Lancaster Antidepressants for smoking cessation In: The Cochrane Library, Issue 4 2004 Wiley Chichester, UK
11. J.R. Hughes L.F. Stead T. Lancaster Anxiolytics and antidepressants for smoking cessation In: The Cochrane Library, Issue 4 2000 Wiley Chichester, UK
12. T. Lancaster L.F. Stead Silver acetate for smoking cessation In: The Cochrane Library, Issue 3 1997 Wiley Chichester, UK
13. S.G. Gourlay L.F. Stead N.L. Benowitz Clonidine for smoking cessation In: The Cochrane Library, Issue 3 2000 Wiley Chichester, UK
14. L.F. Stead J.R. Hughes Lobeline for smoking cessation In: The Cochrane Library, Issue 3 1997 Wiley Chichester, UK
15. T. Lancaster L.F. Stead Mecamylamine (a nicotine antagonist) for smoking cessation In: The Cochrane Library, Issue 2 1998 Wiley Chichester, UK
16. S. David T. Lancaster L.F. Stead Opioid antagonists for smoking cessation In: The Cochrane Library, Issue 3 2001 Wiley Chichester, UK
17. R. West A. McNeill M. Raw Smoking cessation guidelines for health professionals: An update. Health Education Authority Thorax 55 2000 987-999
18. M.C. Fiore W.C. Bailey S.J. Cohen et al. Treating Tobacco use and dependence. Clinical practice guideline 2000 US Department of Health and Human Services, Public Health Service Rockville, MD
19. A.H. Glassman J.E. Helzer L.S. Covey et al. Smoking, smoking cessation, and major depression J Am Med Assoc 264 1990 1546-1549
20. R.J. West P. Hajek M. Belcher Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking Psychol Med 19 1989 981-985
21. J.D. Killen S.P. Fortmann H.C. Kraemer A. Varady B. Newman Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation J Consult Clin Psychol 60 1992 797-801
22. R. Richmond N. Zwar Review of bupropion for smoking cessation Drug Alcohol Rev 22 2003 203-220
23. National Institute of Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. NICE. March 2002. Available at: www.nice.org.uk. Last accessed 15 May 2005.
24. R.D. Hurt D.P. Sachs E.D. Glover et al. A comparison of sustained-release bupropion and placebo for smoking cessation N Engl J Med 337 1997 1195-1202
25. J.T. Hays R.D. Hurt N.A. Rigotti et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial Ann Intern Med 135 2001 423-433
26. D.E. Jorenby S.J. Leischow M.A. Nides et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation N Engl J Med 340 1999 685-691
27. S. Shiffman J.A. Johnston M. Khayrallah et al. The effect of bupropion on nicotine craving and withdrawal Psychopharmacology (Berl) 148 2000 33-40
28. D. Tashkin R. Kanner W. Bailey et al. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial Lancet 357 2001 1571-1575
29. S. Tonstad C. Farsang G. Klaene et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study Eur Heart J 24 2003 946-955
30. R.D. Hurt J.E. Krook I.T. Croghan et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking J Clin Oncol 21 2003 914-920
31. Committee on Safety of Medicines and the Medicines Control Agency. Zyban (bupropion [amfebutamone]) - safety reminder. Curr Probl Pharmacovigilance February 2001.
32. GlaxoSmithKline. Zyban (Bupropion hydrochloride) summary of product characteristics: GlaxoSmithKline; 2001.
33. G.E. Swan L.M. Jack S. Curry et al. Bupropion SR and counseling for smoking cessation in actual practice: Predictors of outcome Nicotine Tob Res 5 2003 911-921
34. A. Oke V. Adhiyaman K. Aziz A. Ross Dose-dependent seizure activity associated with fluoxetine therapy Q J Med 94 2001 113-114
35. Medicines Control Agency. Zyban (bupropion hydrochloride) - safety update. 24 July 2002; http://www.mca.gov.uk/ourwork/monitorsafequalmed/ safetymessages/zyban26702.pdf. Last accessed 4 January 2004.
36. BNF. British national formulary, vol 44. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; September, 2002.
37. A.V. Prochazka M.J. Weaver R.T. Keller G.E. Fryer P.A. Licari D. Lofaso A randomized trial of nortriptyline for smoking cessation Arch Intern Med 158 1998 2035-2039
38. S.M. Hall G.L. Humfleet V.I. Reus R.F. Munoz J. Cullen Extended nortriptyline and psychological treatment for cigarette smoking Am J Psychiatry 161 2004 2100-2107
39. S.M. Hall V.I. Reus R.F. Munoz et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking Arch Gen Psychiatry 55 1998 683-690
40. P. Hajek F. Gillison H. McRobbie Stopping smoking can cause constipation Addiction 98 2003 1563-1567
41. J.S. Fowler G.J. Wang N.D. Volkow et al. Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence Am J Psychiatry 157 2000 1864-1866
42. R. Biberman R. Neumann I. Katzir Y. Gerber A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation Addiction 98 2003 1403-1407
43. E.J. Houtsmuller J.A. Thornton M.L. Stitzer Effects of selegiline (L-deprenyl) during smoking and short-term abstinence Psychopharmacology 163 2002 213-220
44. T.P. George J.C. Vessicchio A. Termine P.I. Jatlow T.R. Kosten S.S. O'Malley A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation Biol Psychiatry 53 2003 136-143
45. I. Berlin S. Said O. Spreux-Varoquaux et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers Clin Pharmacol Ther 58 1995 444-452
46. I. Berlin H.J. Aubin A.M. Pedarriosse A. Rames S. Lancrenon G. Lagrue Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation Addiction 97 2002 1347-1354
47. R. West P. Hajek What happens to anxiety levels on giving up smoking? Am J Psychiatry 154 1997 1589-1592
48. O.F. Pomerleau Endogenous opioids and smoking: A review of progress and problems Psychoneuroendocrinology 23 1998 115-130
49. A.M. Epstein A.C. King Naltrexone attenuates acute cigarette smoking behavior Pharmacol Biochem Behav 77 2004 29-37
50. R. West Glucose for smoking cessation: Does it have a role? CNS Drugs 15 2001 261-265
51. J. Foulds M. Burke M. Steinberg J.M. Williams D.M. Ziedonis Advances in pharmacotherapy for tobacco dependence Expert Opin Emerg Drugs 9 2004 39-53
52. M.S. Cousins H.M. Stamat H. de Wit Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking Nicotine Tob Res 3 2001 123-129
53. P. Pentel D. Malin A vaccine for nicotine dependence: Targeting the drug rather than the brain Respiration 69 2002 193-197
54. M.F. Murphy K. Hey E. Johnstone et al. Bromocriptine use is associated with decreased smoking rates Addict Biol 7 2002 325-328
55. R.D. Hurt J.E. Ahlskog G.A. Croghan et al. Carbidopa/levodopa for smoking cessation: A pilot study with negative results Nicotine Tob Res 2 2000 71-78